Date | Source | Rubrik | Type | Alternative |
---|---|---|---|---|
2024-04-26 | Karolinska Development AB (publ) | Interim Report - January-March 2024 | Pressreleaser | Show Close |
Pressreleaser |
Interim Report – January-March 2024STOCKHOLM – 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report – January-March 2024. The full report is available on the Company’s website. “2024 has begun strongly with development within the respective portfolio companies proceeding according to plan. The adverse market climate we have previously experienced notwithstanding, our portfolio companies have continued tirelessly to advance the development of tomorrow’s treatments in order that patients can reap the benefits as quickly as possible. We look forward to an increasing tailwind and further progress during the year”, says Viktor Drvota, CEO, Karolinska Development. Significant events during the first quarter
Financial update First quarter
The Interim Report for Karolinska Development AB for the period January-March 2024 is available as a PDF at www.karolinskadevelopment.com . For further information, please contact: Viktor Drvota, CEO, Karolinska Development AB Hans Christopher “HC” Toll, CFO, Karolinska Development AB TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients’ lives while providing an attractive return on investment to shareholders. Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success. Karolinska Development has established a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases. The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network. For more information, please visit www.karolinskadevelopment.com
Attachments |
||||
2024-04-26 | Karolinska Development AB (publ) | Delårsrapport för januari – mars 2024 | Pressreleaser | Show Close |
|
||||
2024-04-16 | Karolinska Development AB (publ) | Aktieägarna i Karolinska Development AB (publ) kallas till årsstämma | Pressreleaser | Show Close |
|
||||
2024-04-16 | Karolinska Development AB (publ) | Notice of Annual General Meeting in Karolinska Development AB (publ) | Pressreleaser | Show Close |
|
||||
2024-03-22 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Umecrine Cognition presenterar positiva säkerhetsdata från första delen av bolagets fas 1b/2-studie i PBC | Pressreleaser | Show Close |
|
||||
2024-03-22 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC | Pressreleaser | Show Close |
|
||||
2024-03-22 | Karolinska Development AB (publ) | Karolinska Development Annual Report 2023 published | Rapporter | Show Close |
|
||||
2024-03-22 | Karolinska Development AB (publ) | Karolinska Developments årsredovisning för 2023 har publicerats | Rapporter | Show Close |
|
||||
2024-03-14 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million | Pressreleaser | Show Close |
|
||||
2024-03-14 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Aprea Therapeutics får IND-godkännande från FDA och säkrar finansiering om USD 34 miljoner | Pressreleaser | Show Close |
|
||||
2024-03-14 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units | Pressreleaser | Show Close |
|
||||
2024-03-14 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Biosergen publicerar prospekt i samband med emission av units | Pressreleaser | Show Close |
|
||||
2024-03-06 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD | Pressreleaser | Show Close |
|
||||
2024-03-06 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Umecrine Cognition presenterar prekliniska Parkinsondata för golexanolon på AD/PD | Pressreleaser | Show Close |
|
||||
2024-02-20 | Penser Access by Carnegie | Penser Access by Carnegie: Karolinska Development - Kraftig substansrabatt | Pressreleaser | Show Close |
|
||||
2024-02-16 | Karolinska Development AB (publ) | Bokslutskommuniké för januari – december 2023 | Pressreleaser | Show Close |
|
||||
2024-02-16 | Karolinska Development AB (publ) | Year-end Report - January-December 2023 | Pressreleaser | Show Close |
|
||||
2024-01-17 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company AnaCardio secures SEK 50 million as part of its Series A investment round | Pressreleaser | Show Close |
|
||||
2024-01-17 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag AnaCardio säkrar 50 MSEK inom ramarna för sin serie A-finansieringsrunda | Pressreleaser | Show Close |
|
||||
2024-01-09 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag OssDsign rapporterar exceptionella kliniska data för sitt nanosyntetiska bengraft | Pressreleaser | Show Close |
|
||||
2024-01-09 | Karolinska Development AB (publ) | Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product | Pressreleaser | Show Close |
|
||||
2023-12-06 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag OssDsign bedömer att intäkterna för fjärde kvartalet kommer att överträffa marknadens förväntningar | Pressreleaser | Show Close |
|
||||
2023-12-06 | Karolinska Development AB (publ) | Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates | Pressreleaser | Show Close |
|
||||
2023-12-04 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration | Pressreleaser | Show Close |
|
||||
2023-12-04 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag PharmNovos läkemedelskandidat PN6047 i NIDA-finansierat samarbete | Pressreleaser | Show Close |
|
||||
2023-11-28 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis | Pressreleaser | Show Close |
|
||||
2023-11-28 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Umecrine Cognition presenterar positiv effekt med golexanolon i en preklinisk modell av kolestas | Pressreleaser | Show Close |
|
||||
2023-11-21 | Penser Access | Penser Access: Ett kvartal utan överraskningar - Karolinska Development | Pressreleaser | Show Close |
|
||||
2023-11-17 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Umecrine Cognition säkrar ytterligare finansiering för den kliniska utvecklingen av golexanolon | Pressreleaser | Show Close |
|
||||
2023-11-17 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Umecrine Cognition raises additional funding for the clinical development of golexanolone | Pressreleaser | Show Close |
|
||||
2023-11-17 | Karolinska Development AB (publ) | Delårsrapport för januari – september 2023 | Pressreleaser | Show Close |
|
||||
2023-11-17 | Karolinska Development AB (publ) | Interim Report - January-September 2023 | Pressreleaser | Show Close |
|
||||
2023-11-08 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Modus Therapeutics genomför kapitalanskaffning inför breddning av utvecklingsprogrammet för sevuparin | Pressreleaser | Show Close |
|
||||
2023-11-08 | Karolinska Development AB (publ) | Karolinska Development's portfolio company Modus Therapeutics raises capital to expand the development program for sevuparin | Pressreleaser | Show Close |
|
||||
2023-10-02 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag PharmNovo presenterar positiva data från klinisk fas 1-studie med läkemedelskandidaten PN6047 | Pressreleaser | Show Close |
|
||||
2023-10-02 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company PharmNovo reports positive results from a clinical phase 1 study of drug candidate PN6047 | Pressreleaser | Show Close |
|
||||
2023-09-28 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company PharmNovo reports promising preclinical results on abuse potential and withdrawal symptom relief for its candidate drug PN6047 | Pressreleaser | Show Close |
|
||||
2023-09-28 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag PharmNovo presenterar lovande resultat från en preklinisk studie som visar att inga beroendeframkallande effekter finns samt att lindrande av abstinenssymtom med läkemedelskandidaten PN6047 föreligger | Pressreleaser | Show Close |
|
||||
2023-09-27 | Karolinska Development AB (publ) | Karolinska Development's portfolio company OssDsign raises SEK 150 million and makes strategic move to become a pure play orthobiologics company | Pressreleaser | Show Close |
|
||||
2023-09-27 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag OssDsign tar in SEK 150 miljoner och renodlar sin verksamhet för fullt fokus på ortobiologimarknaden | Pressreleaser | Show Close |
|
||||
2023-09-19 | Karolinska Development AB (publ) | Karolinska Development's portfolio company OssDsign has received FDA clearance for a new major indication | Pressreleaser | Show Close |
|
||||
2023-09-19 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag OssDsign får utökat marknadsgodkännande från FDA för ny betydande indikation | Pressreleaser | Show Close |
|
||||
2023-08-28 | Penser Access | Penser Access: Medvind i de noterade innehaven - Karolinska Development | Pressreleaser | Show Close |
|
||||
2023-08-25 | Karolinska Development AB (publ) | Interim Report - January-June 2023 | Rapporter | Show Close |
|
||||
2023-08-25 | Karolinska Development AB (publ) | Delårsrapport för januari – juni 2023 | Rapporter | Show Close |
|
||||
2023-07-05 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone in a preclinical model of Parkinson’s disease | Pressreleaser | Show Close |
|
||||
2023-07-05 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Umecrine Cognition presenterar resultat från studie av golexanolon i en preklinisk modell av Parkinsons sjukdom | Pressreleaser | Show Close |
|
||||
2023-06-07 | Karolinska Development AB (publ) | Karolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone’s mode-of-action and ability to reduce neuroinflammation | Pressreleaser | Show Close |
|
||||
2023-06-07 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Umecrine Cognition presenterar data som visar golexanolons verkningsmekanism och förmåga att minska neuroinflammation | Pressreleaser | Show Close |
|
||||
2023-05-16 | Karolinska Development AB (publ) | Karolinska Development’s Annual General Meeting 2023 | Pressreleaser | Show Close |
|
||||
2023-05-16 | Karolinska Development AB (publ) | Karolinska Developments årsstämma 2023 | Pressreleaser | Show Close |
|
||||
2023-05-12 | Karolinska Development AB (publ) | Karolinska Developments portföljbolag Modus Therapeutics ser potential för sin läkemedelskandidat sevuparin inom behandling av anemi | Pressreleaser | Show Close |
|
||||
2023-05-12 | Karolinska Development AB (publ) | Karolinska Development's portfolio company Modus Therapeutics sees potential for its drug candidate sevuparin in the treatment of anemia | Pressreleaser | Show Close |
|
||||
2023-05-02 | Penser Access | Penser Access: Med mogen portfölj in i 2023 - Karolinska Development | Pressreleaser | Show Close |
|
||||
2023-04-28 | Karolinska Development AB (publ) | Delårsrapport för januari – Mars 2023 | Pressreleaser | Show Close |
|
||||
2023-04-28 | Karolinska Development AB (publ) | Interim Report - January-March 2023 | Pressreleaser | Show Close |
|